Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol expects a more critical regulatory environment for its recently submitted muraglitazar NDA. Greater scrutiny by FDA could translate into more focused labeling, CEO Dolan says.
You may also be interested in...
Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility
Company faces the possibility of nearly 12 months of limited supply of the rheumatoid arthritis therapy until third-party manufacturer Lonza is approved by FDA, which could occur in mid-2006. Bristol completed the abatacept rolling BLA at the end of March and has requested a priority review.
Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility
Company faces the possibility of nearly 12 months of limited supply of the rheumatoid arthritis therapy until third-party manufacturer Lonza is approved by FDA, which could occur in mid-2006. Bristol completed the abatacept rolling BLA at the end of March and has requested a priority review.
Pravachol OTC Deal Reached Between Bayer, Bristol
Bristol will handle the regulatory filing of the switch NDA and advisory committee presentation for pravastatin 20 mg, while Bayer Consumer Care will handle OTC sales and marketing if FDA approves the cholesterol-lowering agent for nonprescription sale.